Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy

The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after (131)I-tositumomab radioimmunotherapy for potential use in treatment planning. METHODS: Tumor-absorbed dose measures were estimated for 130 tumors in 39 rela...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Dewaraja, Yuni K., Schipper, Matthew J., Shen, Jincheng, Smith, Lauren B., Murgic, Jure, Savas, Hatice, Youssef, Ehab, Regan, Denise, Wilderman, Scott J., Roberson, Peter L., Kaminski, Mark S., Avram, Anca M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237694/
https://ncbi.nlm.nih.gov/pubmed/24842891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.113.136044
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados